WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 407232
Description: Aloisine A is a potent and selective CDK/GSK-3 inhibitor. Aloisine A inhibits cell proliferation by arresting cells in both G1 and G2. IC50 data of Aloisine A: Cdc2 (CDK1)/cyclin B (IC50 = 150nM), Cdk2/cyclin A (IC50 = 120nM), Cdk2/cyclin E (IC50 = 400nM), Cdk5/p25 (IC50 = 200nM), Cdk5/p35 (IC50 = 160nM), and GSK-3α (IC50 = 500nM). Aloisine A also inhibits GSK-3β (IC50 = 650nM) and JNK (c-Jun N-terminal kinase) (IC50~3-10μM). Aloisine A blocks the cell cycle in both G1 and G2 phase.
MedKoo Cat#: 407232
Name: Aloisine A
Chemical Formula: C16H17N3O
Exact Mass: 267.1372
Molecular Weight: 267.332
Elemental Analysis: C, 71.89; H, 6.41; N, 15.72; O, 5.98
Synonym: Aloisine A
IUPAC/Chemical Name: 4-(7-butyl-5H-pyrrolo[2,3-b]pyrazin-6-yl)phenol
InChi Key: PRIGRJPRGZCFAS-UHFFFAOYSA-N
InChi Code: InChI=1S/C16H17N3O/c1-2-3-4-13-14(11-5-7-12(20)8-6-11)19-16-15(13)17-9-10-18-16/h5-10,20H,2-4H2,1H3,(H,18,19)
SMILES Code: CCCCC1=C(C2=CC=C(C=C2)O)NC3=C1N=CC=N3
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 267.332 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Rivest P, Renaud M, Sanderson JT. Proliferative and androgenic effects of
indirubin derivatives in LNCaP human prostate cancer cells at sub-apoptotic
concentrations. Chem Biol Interact. 2011 Feb 1;189(3):177-85. doi:
10.1016/j.cbi.2010.11.008. Epub 2010 Nov 25. PubMed PMID: 21111724.
2: Rowe J, Greenblatt RJ, Liu D, Moffat JF. Compounds that target host cell
proteins prevent varicella-zoster virus replication in culture, ex vivo, and in
SCID-Hu mice. Antiviral Res. 2010 Jun;86(3):276-85. doi:
10.1016/j.antiviral.2010.03.007. Epub 2010 Mar 20. PubMed PMID: 20307580; PubMed
Central PMCID: PMC2866756.
3: Corbel C, Haddoub R, Guiffant D, Lozach O, Gueyrard D, Lemoine J, Ratin M,
Meijer L, Bach S, Goekjian P. Identification of potential cellular targets of
aloisine A by affinity chromatography. Bioorg Med Chem. 2009 Aug
1;17(15):5572-82. doi: 10.1016/j.bmc.2009.06.024. Epub 2009 Jun 18. PubMed PMID:
4: Mettey Y, Gompel M, Thomas V, Garnier M, Leost M, Ceballos-Picot I, Noble M,
Endicott J, Vierfond JM, Meijer L. Aloisines, a new family of CDK/GSK-3
inhibitors. SAR study, crystal structure in complex with CDK2, enzyme
selectivity, and cellular effects. J Med Chem. 2003 Jan 16;46(2):222-36. PubMed